Skip to content
Company Analysis

Tonix Pharmaceuticals Holding C TNXP

A comprehensive view of key metrics, scores, and financial health for Tonix Pharmaceuticals Holding C

Overview of Tonix Pharmaceuticals Holding Corp.

TNXP NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Tonix Pharmaceuticals Holding Corp. (TNXP), is a Micro Cap company, in the Biotechnology industry, last closed at $5.37, about 0.0% overvalued vs fair value, -71.2% 1Y return, placing in the top 25% of its sector.
Metrics Rev Growth 29.8% ROE -64.5% Gross Margin 49.3%
USD 5.37
-0.37%
(Delayed)
• Vol 90d: 65.5%
52-Week Range
Market Cap
$92.10M
Enterprise Value
$-84.13M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 88%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.tonixpharma.com
HQ Chatham, NJ
Employees 81
Fiscal year Dec 31

Next Events

Earnings Nov 9

Fair Value Snapshot

Bear Base Bull
$-10
$-10
$-10
Current: $5.37

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$207.6M
110.2%%
Total Revenue
$13.1M
29.8%%
Net Income
-$124.0M
4.6%%
Operating Expense
$129.2M
66.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
25.0 months
Excellent

Strong cash position with 2+ years of runway

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Tonix Pharmaceuticals Holding C's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
41
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.76), with margins expanding over time.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.69), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.10), raising refinancing risk.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.34), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
37
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing TNXP's balance between Growth (1.1%), Profitability (29.6%), and Safety (69.3%). Growth 1% Safety 69% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

1th percentile vs peers
1
Key Signals
TSR -95.6% 1p
Strengths
  • Cash to Debt Ratio in top 20% of peers (158.62, 94th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks
  • Growth in bottom 20% of peers (percentile: 1)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

78th percentile vs peers
78
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Tonix Pharmaceuticals Holding C.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-9.75
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000